BELLEVUE, Wash.--(BUSINESS WIRE)--Feb. 16, 2006--SCOLR Pharma, Inc. (Amex: DDD) announced today that it has successfully completed pilot bioavailability testing in Canada of its Controlled Delivery Technology (CDT(R)) extended release ondansetron tablets. This is the second application of its amino acid technology. The testing results provide further evidence that SCOLR's patented amino acid CDT-based platform may be a viable alternative to currently utilized solubility and permeability-enhancing practices.
